Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years of age~2. Currently experiencing severe night vision difficulty as reported subjectively~3. At least two patches below the normal range at any two frequencies in Contrast Sensitivity done under mesopic conditions with glare~4. Improvement in low contrast visual acuity (LCVA) in dim light during illumination of contralateral eye~5. Good general health~6. Written informed consent to participate in this trial~7. Ability to comply with all protocol mandated procedures and to attend all scheduled office visits~Exclusion Criteria:~1. Patients with untreated cataracts grades 1-4~2. Patients who wear contact lenses~3. Less than 5 weeks post-refractive surgery (LASIK or PRK)~4. Less than 5 weeks post intraocular lens insertion~5. Low blood pressure (systolic \<120 mm Hg or diastolic \<80 mm Hg)~6. A history of heart rate abnormalities~7. Administration of any investigational drug within 30 days of study initiation~8. Use of any eye drops with a pharmacologic effect on the pupil within 7 days of Visit 1~9. Use of any systemic alpha adrenergic antagonists (Appendix 1)~10. Known local or systemic hypersensitivity to adrenergic antagonists~11. For women of childbearing potential: currently pregnant or lactating, or unwilling to use birth control during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phentolamine Mesylate Ophthalmic Solution 1% (Type: EXPERIMENTAL): 1 drop in each eye (QD) for one day.
- Phentolamine Mesylate Ophthalmic Solution Vehicle (Type: PLACEBO_COMPARATOR): 1 drop in each eye (QD) for one day.

Based on this trial design, predict the completion outcome and termination type (if applicable).